Take­da strikes $500M+ deal for Cal­i­for­nia biotech's ALS pro­gram

Take­da is bet­ting more than half a bil­lion dol­lars on a Cal­i­for­nia biotech’s ap­proach to treat­ing amy­otroph­ic lat­er­al scle­ro­sis (ALS) and oth­er neu­rode­gen­er­a­tive dis­eases.

The Japan­ese phar­ma gi­ant has inked a $580 mil­lion deal (in­clud­ing an undis­closed up­front pay­ment and po­ten­tial mile­stones) for AcuraStem’s PIK­FYVE ther­a­pies, in­clud­ing an ALS can­di­date near­ing the clin­ic called AS-202. By sup­press­ing lev­els of the PIK­FYVE ki­nase, which was re­cent­ly iden­ti­fied as a tar­get for ALS, AcuraStem hopes it can clear out tox­ic pro­tein ag­gre­gates and pro­tect neu­ronal func­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER